Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Urinary Bladder Neoplasms 18Pancreatic Neoplasms 17Lung Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Biliary Tract Neoplasms 10Urethral Neoplasms 9Lymphoma 8Uterine Cervical Neoplasms 6Ovarian Neoplasms 6Gallbladder Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Large-Cell, Anaplastic 4Hodgkin Disease 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Sarcoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Salivary Gland Neoplasms 2Recurrent Uterine Corpus Sarcoma 2Recurrence 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Immunoblastic Lymphadenopathy 2Fallopian Tube Neoplasms 2Adenocarcinoma of Lung 2

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Sarcoma × Gemcitabine × Clear all
NCT00114218 2019-01-08

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

GOG Foundation

Phase 2 Completed
28 enrolled 7 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡